Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring Drug Levels in Rheumatic Autoimmune Diseases
NCT03122431Phase 4Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thalidomide and hydroxychloroquine in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (3 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoints: Serum Levels of Thalidomide at 12 months and Serum Levels of Hydroxycloroquine at 12 months. Started Jun 2017; status: completed.
02
Drugs
thalidomidehydroxychloroquine
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT03122431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122431.